Trump GLP-1 Pilot Program Could Boost Novo Nordisk & Eli Lilly

The pharmaceutical sector experienced short-term volatility, including President Trump's threat of 250% tariffs on imported drugs, contributing to a 5.13% YTD sector decline. However, a significant long-term catalyst emerged for anti-obesity drug leaders Eli Lilly and Novo Nordisk: the Trump administration's proposed plan to expand Medicare and Medicaid coverage for costly GLP-1 weight-loss medications starting in 2026/2027. This policy shift is poised to vastly increase market access for their flagship drugs, positioning the duopoly for substantial future sales growth in a global anti-obesity market projected for a 31.66% CAGR through 2030, potentially offsetting recent stock underperformance despite initial tariff concerns.

Analysis

The healthcare sector is currently facing significant headwinds, evidenced by its 5.13% year-to-date loss and a recent 2.74% five-day decline spurred by presidential threats of up to 250% tariffs on imported pharmaceuticals. This macro pressure has compounded company-specific issues for the two dominant players in the GLP-1 market, Eli Lilly (LLY) and Novo Nordisk (NVO). LLY experienced an 11% share price drop following disappointing trial data for an experimental weight-loss pill, while NVO fell 5.79% in five days after narrowly missing Q2 revenue and EPS estimates. However, these short-term challenges are contrasted by a powerful long-term structural catalyst: a proposed Trump administration plan to extend Medicare and Medicaid coverage to their flagship anti-obesity drugs, like Mounjaro and Wegovy, starting in 2026 and 2027. This regulatory shift would unlock a vast new market, addressing the high out-of-pocket costs that currently limit access. Despite recent stock underperformance, both companies exhibit strong underlying fundamentals; LLY beat Q2 earnings and raised 2025 guidance, while NVO's key drug sales (Ozempic and Wegovy) grew 16% year-over-year. This positions the duopoly to capture a significant share of a global weight loss drug market projected to grow at a 31.66% CAGR through 2030.

Key Decisions for Investors

• Investors should evaluate the significant year-to-date stock price declines in Eli Lilly (-14.49%) and Novo Nordisk (-44.22%) as a potential dislocation between short-term sentiment and the long-term secular growth driven by the GLP-1 market.
• The primary investment thesis hinges on the proposed Medicare and Medicaid coverage expansion; therefore, it is critical to monitor all regulatory and political developments related to the CMMI pilot program, as any delays or changes represent a material risk.
• Given the established duopoly in the anti-obesity drug market, consider exposure to both LLY and NVO to mitigate single-company risk from clinical trial outcomes or specific operational issues, while capturing the broader market growth.
• Remain attentive to short-term volatility catalysts, including rhetoric on pharmaceutical tariffs and competitive data releases, which could present tactical trading opportunities or require adjustments to position sizing.